Intravitreal bevacizumab for severe vaso-occlusive retinopathy in systemic lupus erythematosus
- Authors
- Lee, Won June; Cho, Hee Yoon; Lee, Yoon Jung; Lee, Byung Ro; Shin, Jae Pil
- Issue Date
- Jan-2013
- Publisher
- SPRINGER HEIDELBERG
- Keywords
- Bevacizumab; Lupus retinopathy; Severe vaso-occlusive retinopathy; Systemic lupus erythematosus; Vascular endothelial growth factor; Vasculitis
- Citation
- RHEUMATOLOGY INTERNATIONAL, v.33, no.1, pp.247 - 251
- Indexed
- SCIE
SCOPUS
- Journal Title
- RHEUMATOLOGY INTERNATIONAL
- Volume
- 33
- Number
- 1
- Start Page
- 247
- End Page
- 251
- URI
- https://scholarworks.bwise.kr/hanyang/handle/2021.sw.hanyang/163739
- DOI
- 10.1007/s00296-011-2139-9
- ISSN
- 0172-8172
- Abstract
- Severe vaso-occlusive retinopathy is a relatively rare form of retinopathy in systemic lupus erythematosus (SLE). We report two patients with severe vaso-occlusive retinopathy in SLE who were treated with intravitreal bevacizumab (IVB). (Patient 1) A 35-year-old woman presented with left visual loss and was diagnosed with SLE after systemic evaluation. Despite systemic immunosuppressive therapy, retinal vascular obstruction progressed and neovascularization of the disk (NVD) developed. The patient was treated with IVB and pan retinal photocoagulation. The progression of vascular obstruction ceased and regressed. (Patient 2) A 24-year-old man with SLE presented with left visual loss. There was retinal vascular obstruction with macular edema in both eyes, and then the patient was treated with IVB. One month after injection, minimal capillary nonperfusion increased to 10 disk area, and 5 months later, neovascularization elsewhere (NVE) developed in the right eye. Six months after injection, vitreous hemorrhage with florid NVE and NVD developed in the left eye. In selected severe vaso-occlusive retinopathy in SLE patients, IVB may be an adjuvant option for treatment.
- Files in This Item
-
Go to Link
- Appears in
Collections - 서울 의과대학 > 서울 안과학교실 > 1. Journal Articles
![qrcode](https://api.qrserver.com/v1/create-qr-code/?size=55x55&data=https://scholarworks.bwise.kr/hanyang/handle/2021.sw.hanyang/163739)
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.